Name: UMIN ID:
Unique ID issued by UMIN | UMIN000011867 |
---|---|
Receipt number | R000013840 |
Scientific Title | A randomized phase II study of Regorafenib vs S-1 plus Bevacizumab therapy for advanced/recurrent colo-rectal cancer after treatments including fluoropyrimydine, oxaliplatin, irinotecan, anti-VEGF and anti-EGFR (OGSG 1301) |
Date of disclosure of the study information | 2013/09/25 |
Last modified on | 2022/11/06 00:33:55 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/09/25 23:21:24 | ||
2 | Update | 2014/09/25 19:10:53 | Anticipated trial start date Last follow-up date |
|
3 | Update | 2014/09/25 19:18:06 | Institutions |
|
4 | Update | 2015/05/03 08:16:53 | Institutions |
|
5 | Update | 2015/06/10 00:57:00 | Email |
|
6 | Update | 2015/10/09 22:32:34 | Institutions |
|
7 | Update | 2015/10/09 22:34:18 | Recruitment status Last follow-up date |
|
8 | Update | 2016/10/19 22:59:53 | Name of primary person or sponsor Organization |
|
9 | Update | 2018/04/30 23:56:28 | Email |
|
10 | Update | 2018/05/10 20:34:49 | Email |
|
11 | Update | 2018/08/01 21:44:47 | UMIN ID1 |
|
12 | Update | 2018/08/01 21:47:59 | Name of person sending information Name of person sending information Organization Organization Division name Division name Address Address TEL Institute |
|
13 | Update | 2018/10/07 13:41:45 | Recruitment status Last follow-up date |
|
14 | Update | 2018/10/07 13:57:58 | Last follow-up date |
|
15 | Update | 2020/01/05 20:09:55 | Date of IRB Date analysis concluded |
|
16 | Update | 2020/01/05 20:39:38 | Number of participants that the trial has enrolled Results Delayed Results Delay Reason Results Delay Reason |
|
17 | Update | 2022/11/05 21:51:29 | Recruitment status |
|
18 | Update | 2022/11/05 22:29:46 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Results Delayed Results Delay Reason Results Delay Reason Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
19 | Update | 2022/11/06 00:33:55 | Baseline Characteristics Baseline Characteristics |